You are here: Industry Insights > Nurix

News List

Nurix Therapeutics Appoints Stefani Wolff as COO and EVP, Product Development firstwordpharma
June 22, 2021
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Stefani A. Wolff has joined the company as chief operating officer and executive vice president of product development
Nurix raises $120m financing to advance its protein modulation pipeline pharmaceutical-technology
March 16, 2020
San Francisco based-Nurix has closed its funding round with a total of $120m. The financing was led by Foresite Capital and supported by new investors Bain Capital Life Sciences ...
Nurix Therapeutics, Sanofi Announce Development Collaboration americanpharmaceuticalreview
January 15, 2020
Nurix Therapeutics announced a global strategic collaboration with Sanofi to discover, develop and commercialize a pipeline of targeted protein degradation drugs for patients with challenging diseases in multiple therapeutic areas.
Nurix and Gilead partner on developing protein degradation drugs pharmaceutical-technology
June 21, 2019
Gilead has signed a global collaboration with Nurix to discover, develop and commercialise a pipeline of protein degradation drugs for cancers and other challenging diseases.
Gilead and Nurix to Collaborate on Novel Therapies contractpharma
June 21, 2019
Consisting of targeted protein degradation drugs for patients with cancer and other challenging diseases.
Gilead, Nurix Announce Collaboration to Develop Novel Therapies for Cancer americanpharmaceuticalreview
June 20, 2019
Gilead Sciences and Nurix Therapeutics announced a global strategic collaboration to discover, develop and commercialize a pipeline of innovative targeted protein degradation drugs for patients with cancer and other challenging diseases.